Charles River Laboratories Is Well-Positioned For 2018 (And Beyond)

Summary Points:

- Charles River Labs recently reported impressive Q4 and Full-year 2017 operating results, and one of the company's operating divisions stood out more than the others.

- This small cap company is well-positioned for 2018 [and beyond], so I believe that investors should seriously consider adding CRL shares to their long portfolios.

- Charles River is a long-term buy at today's price.

Charles River Laboratories ($CRL) has been a top performer for the R.I.P. Portfolio over the last year. Additionally, Charles River's most recent operating results show that management has this company well-positioned for 2018 and beyond.

This early-stage research and drug discovery company has shown the financial community over the last year that it has promising business prospects by reporting strong operating results and, as a direct result, the market has rewarded shareholders with a rising stock price.

As shown, CRL shares have outperformed the broader market by a wide margin but, as described in my last article, Charles River is a long-term play. Moreover, it helps that the company's Q4 and Full-year 2017 results showed me that my bull case was still intact.